Navigation Links
Gene Therapy Provides Vision to People who Were Nearly Blind
Date:4/27/2008

Results of Clinical Trial Supported by the Foundation Fighting Blindness

are Published in the New England Journal of Medicine

OWINGS MILLS, Md., April 27 /PRNewswire/ -- Scientists employing a gene therapy have provided partial vision to patients who were nearly blind from a condition known as Leber congenital amaurosis (LCA) -- a severe form of retinitis pigmentosa. Initial results from the clinical trial, which was funded in part by the Foundation Fighting Blindness, were published today in the New England Journal of Medicine.

All three patients, who had severely abnormal vision before entering the study, can now read several lines on an eye chart and are able to see better in dimly lit settings. One was also able to navigate better after the injection.

"This breakthrough is the greatest advancement in the 37-year history of the Foundation Fighting Blindness and the entire history of retinal degenerative disease research. We have achieved a critical milestone in curing a form of childhood blindness," says Gordon Gund, Co-Founder and Chairman of the Foundation Fighting Blindness, which is the largest non-governmental source of funding for this research.

"Our clinical trial results represent an important first step in developing therapies and treatments that will reverse blindness in people with a variety of retinal degenerative diseases," says Jean Bennett, M.D., Ph.D., who is the study's lead researcher at The Children's Hospital of Philadelphia.

"The three participants in the Foundation-supported study at The Children's Hospital of Philadelphia are ages 19-26. Though the trial's main goal was to evaluate safety of the treatment, the research team is very excited about the participants' improvements in vision," says Stephen Rose, Ph.D., Chief Research Officer, Foundation Fighting Blindness.

This Phase I study will continue through its planned enrollment of nine individuals between the ages of 8 and 27. T
'/>"/>

SOURCE Foundation Fighting Blindness
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Dr. Calvin Grant Presents Results from Xibrom(TM) Combination Therapy with Lucentis(R) at the 2008 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO)
2. FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment
3. In Blood Vessel Stents, Innovative Materials Allow Better Control, Delivery of Gene Therapy
4. Karmanos Researchers Find Non-Toxic Agents Added to Conventional Chemotherapy Decrease Survival of Colon Cancer Cells
5. ALS Therapy Development Institute Signs Collaboration Agreement with the Allen Institute for Brain Science
6. MAP Pharmaceuticals Reports Positive Results From Phase 2a Clinical Trial of Combination Therapy in Adult Asthmatics
7. CV Therapeutics Anti-Ischemic Therapy Ranexa(R) Significantly Reduces Cardiac Chest Pain Symptoms and Recurrent Ischemia in MERLIN-TIMI 36 Patients With Angina
8. Final Data From the Bioheart Seismic Trial Suggest Safety, Efficacy of Autologous Stem-Cell Therapy for Treating Congestive Heart Failure
9. Final Data From the SEISMIC Trial Suggest Safety, Efficacy of Autologous Stem- Cell Therapy for Treating Congestive Heart Failure
10. NeoVista Presents One Year Data on Novel Wet AMD Therapy at Macula Society
11. Early Research Suggests Umbilical Cord Blood Cell Therapy May Reduce Progression of Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2008)...ewswire/ -- FluoroPharma Inc., a company developin...sitron Emission Tomography,(PET) market, announced...orine-18 labeled tracer for myocardial perfusion i...lar product to complete Phase I clinical,developme...sess the blood flow in the,heart (myocardial perfu...
(Date:7/23/2008)...23 /- InCode BioPharmaceutics, Inc.,...nced preclinical test,results demonstrating the ut...reatment of the rare chronic blood disorder paroxy...results will be presented at the XXII,Internationa...mber 28,2008., The only treatment currently avai...
(Date:7/23/2008)...ND-Enabling Work with Protein Therapeutics that ... System, CAMBRIDGE, Mass., July 23 /... initiated a corporate growth plan with the,appoin... officer and the,establishment of its headquarters...f Emlen, M.D., a co-founder of the company who rem...
(Date:7/22/2008)...sults from a multi-center 293-patient European, t... Exchange Symbol: CYT, MONTREAL, July 22 /PRNewsw...e global leader in cryotherapy products to treat c...reviously presented from three,European study cent...(R),were published earlier today in the Journal o...
Breaking Medicine Technology:FluoroPharma Announces Positive Phase I Safety Results for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET) 2FluoroPharma Announces Positive Phase I Safety Results for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET) 3InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) 2Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters 2Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters 3CryoCath Arctic Front(R) Results Published in JACC 2CryoCath Arctic Front(R) Results Published in JACC 3Access Highlighted in Recent BusinessWeek Article 498 1Access Highlighted in Recent BusinessWeek Article 498 2Prescription labels geared toward pharmacies not patients 982 1Prescription labels geared toward pharmacies not patients 982 2Scientists fear rare dolphin driven to extinction by human activities 345 1Scientists fear rare dolphin driven to extinction by human activities 345 2IVCC launches groundbreaking insecticide projects with Bayer and Syngenta 978 1IVCC launches groundbreaking insecticide projects with Bayer and Syngenta 978 2
(Date:7/25/2008)...ncial results -, LAVAL, QC, July 25 /PRNewswire-F...) today announced that it will host a conference c...ss its second quarter 2008,financial results. Labo...l,results via news release at approximately 7:00 a...by telephone, dial 416-646-3095 or,1-800-814-4859....
(Date:7/25/2008)...stCall/ -- Thoratec,Corporation (Nasdaq: THOR ) a...ry support therapies to save, support and restore ...t its operating results for the second,quarter and... 31., The company will hold a conference call to ...ties to all interested parties at 1:30 p.m.,Pacif...
(Date:7/25/2008)...unction, increases asthma risk, studies find, ,... clean, fresh-smelling home may actually be bad fo...and air freshening products you use. , Recent r...s or air fresheners that contain a certain volatil...ne (1,4 DCB), can reduce lung function by 4 percen...
(Date:7/25/2008)... Society for Gastrointestinal Endoscopy (ASGE) has... bariatric surgery patient. The rising prevalence ... surgical interventions led to a marked increase i... the U.S., from 13,365 in 1998 to 102,794 in 2003....ive patient and the postoperative patient, and app...
Breaking Medicine News(10 mins):Health News:Labopharm to host conference call Friday, August 8, 2008 at 8:30 A.M. (ET) 2Health News:Thoratec Schedules Second Quarter 2008 Conference Call, Webcast 2Health News:Health Hazards in Household Cleaners Exposed 2Health News:Health Hazards in Household Cleaners Exposed 3Health News:ASGE issues guidelines on the role of endoscopy in the bariatric surgery patient 2Health News:ASGE issues guidelines on the role of endoscopy in the bariatric surgery patient 3
...nder affects learning have found that boys and gir...rent ways. However, they have suggested that thi...er their kids from co-educational to segregated sc...American educator Michael Gurian, at a conference ...
...co will kill a billion people this century, 10 tim... unless the countries take serious action to preve...re assuming that by putting one cigarette to your ...if you sniff-up someone else's smoke only once, yo...
...first manned mission to Mars, it has taken its fir...o you get rid of the body of a dead astronaut on a...the plug be pulled on a critically ill astronaut w...ngering the rest of the crew? Should NASA employ D...
...reveals the war veterans who have come back after ...nt. Due to the exposure to chemicals and other har...o brain regions that are closely linked to learnin...of the department of environmental health at the B...
Other Medicine News:Health News:Boys and Girls are Different by Nature and Learn in Different Ways 2Health News:1 Billion People to Be Killed by Smoking 2Health News:NASA Gets Ready To Address Tough Questions 2Health News:NASA Gets Ready To Address Tough Questions 3Health News:Gulf War Veterans Exhibit Memory Impairment 2
...ut patients negative for antinuclear antibodies, w...c diseases such as Systemic lupus erythematosus (L...disease, progressive systemic sclerosis, scleroder...henomenon. They can also be used in conjunction wi...
The PANBIO Inc. Indirect Fluorescence Assay (IFA) for IgG Antinuclear Antibody (ANA) HEp2 is intended for the qualitative and semi-quantitative detection of IgG (Immunoglobulin G) antinuclear antibod
The VerifyNow Clopidogrel Assay measures changes in platelet function in response to patients taking Clopidogrel (Plavix). It uses a specific activator for the P2Y12 pathway, which clopidogrel inhibi
The Wide Angle Twin Mag NP combines the performance of two instruments to deliver unequalled power and versatility into the hands of eye care professionals.
Medicine Products: